Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.87 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.87 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL4917618 | 0.95 | ADRB2 (0.86) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL7266244 | 0.95 | ADRB2 (0.79) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL458736 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL4247 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Formoterol SCHEMBL349579 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL6547706 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL3679114 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL117865 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Formoterol SCHEMBL6528975 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Formoterol SCHEMBL15856256 | 0.93 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814752-B2 | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150283202-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | BAUSCH HEALTH COMPANIES INC. (CA) | 2015-10-08 | — | — | US | disclosed |
| EP-2583668-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7541385-B2 | Bronchodilating β-agonist compositions and methods | MYLAN TECHNOLOGIES, INC. | 2009-06-02 | — | — | US | disclosed |
| EP-1064040-A1 | VALVE FOR AEROSOL CONTAINER | GLAXO GROUP LIMITED (GB) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047195-A1 | VALVE FOR AEROSOL CONTAINER | GLAXO GROUP LIMITED (GB) | 1999-09-23 | — | — | WO | disclosed |